Using of systemic
enzymotherapy for treatment of rheumatoid arthritis.
Kovalenko V.,Golovkov Y., Golovatcky
I. Using of systemic enzymotherapy for treatment of rheumatoid
arthritis. Rheumatologia 1998, Suppl., Vol. XXXVI, Warsaw 1998, Abst.
No. 140, pp. 206.
We applied the drug WOBENZYM (MUCOS Pharma Gmbh & Co., Germany) in
the complex treatment of 25 rheumatoid arthritis (RA) patients (mean
age 62,1+4,4 years), which formed the basic group (BG), parallel
with NSAIDs. In 27 patients of the control group (CG) there were
used only NSAIDs. The both groups were comparable by the age,
severity of their disease, and accompanying diseases.
The intensity of pain syndrome (by 10-scale) reduced in pts of BG
from 6,85±0,28 to 2,80+0,19 units /u./ (p<0,01), while in pts of CG
from 7,04±0,26 to 3,87±0,24 (p<0,01), but this reduction was more
pronounced in pts of BG (p<0,01).
Pain reduction by 50% was observed in 85% of BG but only in 39,1% of
CG pts (p<0,05). Patient self-evaluation of treatment efficacy
coincided with physician evaluation in 87,5% of BG pts, while in CG
-68% (p<0,05). There was observed positive dynamics of Stanford form
indices: from 31,2±3,5 to 22,1±3,4 in the BG (p<0,05), while in the
CG changes were insignificant. Also we have observed increase of
hand strength in BG and CG by 4,52±0,86 kg and 2,27±0,51 kg,
accordingly (p<0,05). We have not observed adverse reactions in BG,
while in 20% of CG pts (p<0,01). By infrared thermography data
resumption of inflammatory process, or its essential reduction was
stated, ESR also decreased (p<0,05).Thus WOBENZYM application in
complex treatment of RA pts permits to get effective curative
results at absence of indesirable effects.